4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
Want to see FDMT full AI Analyst Report?
Top Page
4D Molecular Therapeutics
(NASDAQ:FDMT)
Select Model
Select Model
Rating:52Neutral
Price Target:
$10.50
▲(0.10% Upside)
Action:ReiteratedDate:03/31/26
The score is held down primarily by weak financial performance (pre-commercial revenue, large losses, and ongoing cash burn), partially offset by a relatively strong, low-leverage balance sheet. Technicals are moderately supportive, while valuation remains challenged due to negative earnings and no dividend. Corporate events are mildly positive but secondary to the financial profile.
Positive Factors
Low leverage / strong balance sheet
A very low debt burden and sizable equity/assets provide durable financial flexibility for a clinical-stage biotech. This reduces near-term refinancing risk, supports continued R&D spend and trial execution, and makes the company better positioned to absorb operating losses or pursue partnerships without immediate distress.
Negative Factors
Large cash burn
Sustained negative operating and free cash flow represents a structural funding requirement. Continued cash burn necessitates external capital or partner funding, increasing dilution or reliance on milestone-based receipts and constraining the company’s ability to self-fund multiple late-stage programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
A very low debt burden and sizable equity/assets provide durable financial flexibility for a clinical-stage biotech. This reduces near-term refinancing risk, supports continued R&D spend and trial execution, and makes the company better positioned to absorb operating losses or pursue partnerships without immediate distress.
Read all positive factors
4D Molecular Therapeutics (FDMT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$479.88M
Dividend YieldN/A
Average Volume (3M)736.92K
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue Growth230194.59%
EPS Growth20.52%
CountryUS
Employees227
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.43
Shares Outstanding51,051,487
10 Day Avg. Volume751,996
30 Day Avg. Volume736,921
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)0.86
Price to Sales (P/S)5.10
P/FCF Ratio-3.98
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue5.18
Enterprise Value/Gross Profit-36.88
Enterprise Value/Ebitda-2.76
Forecast
1Y Price Target
$30.38Price Target Upside189.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.82
Revenue Forecast (FY)$7.78M
4D Molecular Therapeutics Business Overview & Revenue Model
Company Description
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalm...
How the Company Makes Money
FDMT generates revenue primarily through collaboration and licensing arrangements rather than product sales (its programs are clinical-stage and it has not consistently generated recurring commercial product revenue). Under these agreements, FDMT ...
4D Molecular Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 85.21M | 37.00K | 20.72M | 3.13M | 18.04M |
| Gross Profit | 77.58M | 37.00K | -76.37M | -77.12M | -43.32M |
| EBITDA | -151.92M | -181.14M | -108.66M | -107.63M | -69.81M |
| Net Income | -140.11M | -160.87M | -100.84M | -107.49M | -71.32M |
Balance Sheet | |||||
| Total Assets | 566.71M | 560.38M | 339.89M | 261.85M | 353.49M |
| Cash, Cash Equivalents and Short-Term Investments | 402.65M | 424.88M | 288.23M | 213.55M | 247.78M |
| Total Debt | 21.41M | 24.61M | 14.67M | 16.12M | 16.45M |
| Total Liabilities | 61.05M | 49.78M | 32.06M | 30.51M | 34.38M |
| Stockholders Equity | 505.66M | 510.61M | 307.83M | 231.34M | 319.11M |
Cash Flow | |||||
| Free Cash Flow | -109.08M | -138.37M | -78.56M | -98.22M | -78.24M |
| Operating Cash Flow | -109.08M | -134.59M | -75.79M | -86.69M | -69.13M |
| Investing Cash Flow | -92.97M | -302.44M | 115.72M | -17.05M | -172.68M |
| Financing Cash Flow | 112.96M | 337.25M | 156.83M | 3.08M | 118.09M |
4D Molecular Therapeutics Technical Analysis
Positive
10.49
Price Trends
9.29
Positive
9.17
Positive
8.39
Positive
Market Momentum
0.29
Negative
60.51
Neutral
47.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FDMT, the sentiment is Positive. The current price of 10.49 is above the 20-day moving average (MA) of 9.68, above the 50-day MA of 9.29, and above the 200-day MA of 8.39, indicating a bullish trend. The MACD of 0.29 indicates Negative momentum. The RSI at 60.51 is Neutral, neither overbought nor oversold. The STOCH value of 47.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FDMT.
4D Molecular Therapeutics Risk Analysis
4D Molecular Therapeutics disclosed 87 risk factors in its most recent earnings report. 4D Molecular Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
4D Molecular Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $479.88M | -3.10 | -31.75% | ― | 230194.59% | 20.52% | |
52 Neutral | $772.75M | -7.71 | -32.72% | ― | ― | -39.08% | |
52 Neutral | $390.50M | -5.17 | -43.33% | ― | ― | 32.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $185.91M | -0.64 | -115.95% | ― | 181.46% | -32.98% | |
48 Neutral | $466.37M | -3.10 | -71.25% | ― | ― | -3.52% | |
45 Neutral | $442.09M | -62.28 | -5.63% | ― | 153.52% | 72.62% |
* Healthcare Sector Average
FDMT
4D Molecular Therapeutics
9.40
6.06
181.44%
ASMB
Assembly Biosciences
27.87
17.05
157.58%
KRRO
Korro Bio
12.89
-4.58
-26.22%
DSGN
Design Therapeutics
12.53
8.47
208.62%
IMRX
Immuneering
6.04
4.59
316.55%
AURA
Aura Biosciences Inc
7.27
1.76
31.94%
4D Molecular Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
4D Molecular Therapeutics Consolidates Financial Leadership Under New Role
Positive
Mar 31, 2026
On March 25, 2026, 4D Molecular Therapeutics appointed Chief Financial Officer Kristian Humer as its Principal Accounting Officer, consolidating key financial leadership roles under a single executive. He replaces Ashoo Gupta in this capacity, who...
Business Operations and StrategyRegulatory Filings and Compliance
4D Molecular Therapeutics Restructures Equity via Warrant Exchange
Neutral
Jan 26, 2026
On January 22, 2026, 4D Molecular Therapeutics entered into exchange agreements with RA Capital Healthcare Fund and Biotechnology Value Fund under which these investors swapped a total of 6.6 million shares of the company’s common stock for ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.